• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Technology Review >Is an anti-aging drug around the corner?
【24h】

Is an anti-aging drug around the corner?

机译：拐角处是一种抗衰老药吗？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

One of today's most promising drugs for targeting aging has a long, circuitous history. In 1999, the US Food and Drug Administration approved rapa-mycin as an immunosuppressant to prevent the rejection of transplanted organs. Scientists later found it affected all sorts of biological processes; the "mammalian target of rapamycin" (or mTOR) includes immune function and inflammation.Experiments also showed that rapamycin extended the life span of yeast, worms, and mice. Could it do the same thing in humans?At present, there's no rigorous way to test rapa-mycin's potential to slow human aging. Rather, researchers have zeroed in on a significant aspect of aging-the decline in immune function-to see if drugs that mimic rapamycin can enhance immune function in older people.Joan B. Mannick is cofounder and chief medical officer of a biotech company called resTORbio, spun out of Novartis in 2017, which is conducting clinical trials of RTB101. It's a drug candidate at the forefront of efforts to slow the age-related decline of the immune response. Mannick says we will have our first answer about the potential of this anti-aging intervention within a year.
机译：今天最有希望的靶向老龄化的药物之一具有漫长而迂回的历史。 1999年，美国食品和药物管理局批准了RAPA-MYCIN作为免疫抑制剂，以防止抑制移植器官。科学家后来发现它影响了各种各样的生物过程; “哺乳动物雷帕霉素”（或mTOR）包括免疫功能和炎症。实验还表明雷帕霉素延长了酵母，蠕虫和小鼠的寿命。可以在人类中做同样的事情吗？目前，没有严格的方法来测试Rapa-mycin潜力缓慢衰老。相反，研究人员在老化的重要方面进行了归零 - 免疫功能的下降 - 看药物模拟雷帕霉素可以增强老年人免疫功能。Joan B. Mannick是一家名为Restorbio的Biotech公司的Cofounder和首席医务官，2017年北诺斯出来，正在进行RTB101的临床试验。这是一种毒品候选人，以减缓免疫反应的年龄相关的衰退的最前沿。 Mannick说，我们将在一年内进行关于这种抗衰老干预的潜力的第一个答案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号